G

GSK

Develops medicines, vaccines, and consumer health

Global Study Manager

Full-TimePosted on 10/7/2026Deadline 10/21/26
CA$117k - CA$167k/yr
Senior
Bachelor's
Mississauga, ON, Canada
HybridTwo to three days per week in the Mississauga office; travel within Canada and internationally is required.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • Minimum of 5 years of relevant clinical research or study operations experience.
  • Demonstrated leadership or team-lead experience, such as manager, country study manager, or local delivery lead; experience limited to administrative or CRO coordinator duties is insufficient.
  • Hands-on experience across the study lifecycle, including feasibility, start-up/recruitment, vendor management, and close-out.
  • Project management experience with timeline and budget oversight.
  • Strong stakeholder and cross-functional management experience, locally or globally.
  • A bachelor's degree in life sciences or a related discipline.
  • Fluent English with strong written and verbal communication.
  • Strong project planning, prioritization, and decision-making under uncertainty.
  • Ability to lead effectively in matrixed, multicultural teams and coach and empower others.
  • Analytical, risk-based problem-solving ability and stakeholder communication.
  • Adaptability to multiple therapeutic areas and study designs.
  • Must live in proximity to a GSK hub for the hybrid role.
Responsibilities
  • Deliver clinical operations activities for assigned studies from Commit to Study Initiation through study archiving, in consultation with the Global Study Lead.
  • Lead the Clinical Operations Working Group and be accountable for operational delivery of studies to time, quality, budget, company standards, and scientific requirements; support timely decision-making and lead the study team toward study deliverables.
  • Own operational Working Group deliverables, including the Study Initiation Meeting, Clinical Study Activity Plan, Study Delivery Plan, TMF Quality Strategy Document, decentralized clinical trial setup, Study Demographic and Diversity Plan, Vendors Oversight Plan, Results Dissemination Plan, Investigator/CRA Meeting setup and associated training, Expected Document List, Recruitment Tracking, budget tracking, eTMF filing, vendor setup and management, patient engagement activities, CSDD kickoff meeting and template, Safety Management Plan, Protocol Deviation Management Plan, eTMF and vendor setup, and Pharmacy Manual, adjusted as appropriate for the STOM FSO model.
  • Support assessment and selection of FSO vendors.
  • Provide holistic oversight of FSO vendors according to the FSO handbook.
  • Assess and select other study vendors under GCSD responsibility in consultation with the Global Study Lead.
  • Ensure compliance with ICH/GCP guidelines, applicable laws and regulations, and GSK standard operating procedures for assigned studies, and understand the study's contribution to the program or submission.
  • Make risk-benefit decisions based on a clear understanding of their impact on the study and project.
  • Identify, oversee, and mitigate study risks proactively and effectively.
  • Ensure appropriate stakeholder communication about study status, expectations, risks, and issues.
  • Operate within the study budget.
  • Lead empowered matrix teams effectively.
  • Implement innovative approaches to study delivery using external advances in technology and science, and encourage matrix and line teams to develop innovative perspectives and solutions.
  • Provide operational input into protocol, informed consent form, and other key study document development.
  • Lead and conduct investigator meetings and other study-related meetings.
  • Lead quality efforts to ensure protocol compliance and continual inspection readiness for assigned studies.
  • Ensure data quality plans and end-to-end data cleaning are performed in-stream by the responsible line functions.
  • Ensure timely delivery of the Clinical Study Report and support adherence to local regulatory guidance.
  • Oversee the activities of countries participating in the study.
  • Provide support and coaching to the Study Manager where appropriate.
  • Increase utilization of artificial intelligence and machine learning tools, drive automation of manual processes, and identify efficiencies and more effective ways of working.
Desired Qualifications
  • Global cross-functional management experience.
  • Cross-modal experience and a solid understanding of clinical drug development, which may be assessed in the interview.
  • Experience with electronic Trial Master File (eTMF), Clinical Trial Management Systems (CTMS), and digital/artificial intelligence and machine learning tools.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Associated Press
Oct 19th, 2026
FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

The Reporter
Oct 15th, 2026
Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco.

Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco. Company is currently in tax dispute with local district, township. PUBLISHED: October 15, 2026 at 1:32 PM EDT UPDATED: October 15, 2026 at 1:38 PM EDT UPPER GWYNEDD - Governor Josh Shapiro and Pennsylvania Department of Community and Economic Development Secretary Rick Siger announced on Wednesday that the state has secured a $2.9 billion investment from Merck global biopharmaceutical company to expand its operations in Montgomery County by the end of 2030. Pennsylvania is investing $5 million in the company's expansion, which will support the manufacturing of lifesaving products and medicine discovery, according to a statement from Shapiro and Siger. As part of the $2.9 billion commitment, Merck is investing $550 million in ADVANCE, a state-of-the-art robotics and AI-enabled drug research and development facility at its West Point Campus, and the nearby Springhouse Innovation Park R&D facility, which will help the company produce life-saving medicines. "My administration has made life sciences a key part of our economic development strategy here in Pennsylvania, and Merck's major investment in Montgomery County is another major win for the commonwealth," said Shapiro in a statement from his office. "We are proud to partner with Merck as they expand their operations in Montgomery County, advance cutting-edge research and manufacturing, and create new opportunities for thousands of Pennsylvanians. The life sciences industry is booming in Pennsylvania and I am committed to winning more investments like this and making sure our commonwealth remains a national leader in innovation, medicine, and manufacturing." A week earlier, also in Montgomery County, Shapiro and Siger announced that pharma giant GSK will invest more than $800 million to expand its facilities in King of Prussia, establishing a biopharmaceutical innovation and manufacturing hub, integrating commercial production, research and development and advanced digital capabilities in a single site. Funding from RCAP. Merck received a funding proposal from DCED for a $5 million Redevelopment Assistance Capital Program grant for the first West Point projects. Shapiro and Siger were at Merck's West Point campus Wednesday to help cut the ribbon on the ADVANCE facility. West Point plays a critical role in global public health, manufacturing over 200 million doses of vaccines a year. "Merck's continued investment in Montgomery County is a testament to Pennsylvania's strength as a global hub for life sciences, innovation, and advanced manufacturing," said Siger. "The commonwealth's $5 million RACP investment is helping support projects that will strengthen Merck's operations, advance the development and manufacturing of critical medicines and vaccines, and reinforce our competitive edge in an industry that is extremely important in Pennsylvania." In July, Upper Gwynedd Township officials announced that Merck was developing plans for a new manufacturing facility on their West Point campus, the most recent of several approved and built since the start of the 2020s, including expanding the existing "Building 45" for labs and office space in October 2020, a new "Building 50" of roughly 101,000 square feet of manufacturing space in February 2021, a new "Building 32" for freezer space approved in May 2021, expansion of the proposed "Building 50" in August 2021, and a new "Building 63A" production facility approved in November 2021. Merck also secured approvals in 2024 for a new "Building 41" toward the center of the company's 320-acre complex and in 2025 secured approvals from the township to swap preservation of wetlands on the site for another parcel elsewhere in the region. In September township officials approved the latest plans, for a vaccine manufacturing facility of roughly 75,000 square feet. The company, township, and North Penn School District have also been in a dispute over the firm's tax bill since early May, when Upper Gwynedd's staff asked that township's commissioners to approve a contract for new assessments of two properties township's comprising the West Point campus. In June the district hired a special counsel to handle the matter, and in September the school board created a new fund to keep Merck tax payments separate, saying the company was 'paying in protest' during the dispute. Joining Shapiro and Riger on Wedneday, Rob Davis, chairman and CEO of Merck, said, "The ADVANCE facility represents the future of clinical development at Merck and underscores our continued commitment to addressing the needs of the patients we serve." "This builds on our longstanding presence in Pennsylvania where we're proud to invest in the people, communities and scientific capabilities that will help drive the next generation of medicines," he said.

Seeking Alpha
Oct 14th, 2026
GSK plans more than 1,200 job cuts in Belgium.

GSK plans more than 1,200 job cuts in Belgium. GSK (GSK) plans to cut up to 1,217 jobs in Belgium as part of a proposed restructuring affecting research and development, production, and international support services, according to multiple Belgian media reports. The plan covers 482 white-collar employees and 735 management positions, according to union ABVV Chemie. Production-floor worker positions are reportedly excluded from the proposed reorganization. GSK (GSK) outlined the restructuring at a special works council meeting on Wednesday, October 14. The proposed changes affect GSK Biologicals, the group's vaccine business, according to a local report. GSK (GSK) employs about 8,500 people across its Belgian sites in Wavre, Rixensart and Gembloux. The proposed cuts follow a reduction of more than 400 jobs in Belgium during 2025, mainly through temporary-contract non-renewals and voluntary departure. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.

WZUU
Oct 14th, 2026
GSK to cut up to 1,217 jobs in Belgium, L'Echo says.

GSK to cut up to 1,217 jobs in Belgium, L'Echo says. BRUSSELS, Oct 14 (Reuters) - British biopharmaceutical company GSK is planning to cut up to 1,217 jobs from its Belgium locations, Belgian newspaper L'Echo reported on Wednesday. - The company announced the plan to unions earlier on Wednesday - The company and unions did not immediately respond to requests for comment (Reporting by Makini Brice;Editing by Elaine Hardcastle) Now Playing Too Late For Love DEF LEPPARD

INACTIVE